| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.3 | 2e-09 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-07 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.17 | 8e-07 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.19 | 8e-05 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | -0.3 | 0.0001 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0001 |